About the Authors

Michael Hansen

Roles Data curation, Investigation, Methodology, Project administration

Affiliation Division of Endocrinology, Phoenix VA Medical Center, Phoenix, Arizona, United States of America

Xiaopin Cai

Roles Methodology, Project administration

Current address: Division of Endocrinology, China-Japan Friendship Hospital, Beijing, China

Affiliation Department of Genetics, Cell Biology and Development, University of Minnesota, Minneapolis, Minnesota, United States of America

Sara Bowen

Roles Formal analysis, Methodology, Project administration, Software, Validation, Visualization

Affiliation Flow Cytometry Core Facility, Barrow Neurological Institute, Phoenix, Arizona, United States of America

David A. Largaespada

Roles Funding acquisition, Resources, Supervision, Writing – review & editing

Affiliations Department of Genetics, Cell Biology and Development, University of Minnesota, Minneapolis, Minnesota, United States of America, Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota, United States of America

Ming V. Li

Roles Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing

Ming.Li@va.gov

Affiliations Division of Endocrinology, Phoenix VA Medical Center, Phoenix, Arizona, United States of America, Department of Medicine, University of Arizona College of Medicine, Phoenix, Arizona, United States of America

Competing Interests

The authors have read the journal’s policy and the authors of this manuscript have the following competing interests: DAL is a co-founder and co-owner of NeoClone Biotechnologies, Inc., Discovery Genomics, Inc. (then acquired by Immusoft, Inc.), B-MoGen Biotechnologies, Inc. (then acquired by Bio-Techne Corporation), and Luminary Therapeutics, Inc. DAL holds equity in, serves as a Senior Scientific Advisor for, and on the Board of Directors for Recombinetics, a genome editing company. DAL consults for Genentech, Inc., which is funding some of his research. None of the work described in this manuscript is related to the business of these companies. A provisional patent application with M.V.L listed as inventor has been submitted by Office of Research and Development, Department of Veterans Affairs. The technology described in this manuscript has been filed for patent application under international filing # WO2020087010A1, application # PCT/US2019/058155 and title Compositions and methods for selecting biallelic gene editing. This does not alter our adherence to PLOS ONE policies on sharing data and materials.